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Until the 1980s the diagnosis ofspecific etiologic agents ofinfectious diseases rested with their
isolation in vitro and identification by analysis of their phenotypic characteristics. In the 1970s
the concept of a microbial species evolved from phenotypic analysis to nucleic acid homology.
Currently, nucleic acid sequences specific for a given species are being isolated and amplified and
utilized not only to identify the pathogen after it has been grown in vitro but also elucidate it
directly in biological material. The procedures for making nucleic acid hybridization probes are
analogous to the generation of monoclonal antibody tests. Currently, research and development
are centered in choosing the particular nucleic acid to analyze, establishing the most efficient
vector system for amplifying the nucleic acid, generating an efficient means of selecting the
particular nucleic acid fragment specific for the microorganism, and in measuring the hybridiza-
tion reaction. While immunological techniques have been utilized in the clinical laboratory for
over thirty years, the means ofdetecting nucleic acid hybridization reactions arejustbeginning to
be usable in the clinical diagnostic laboratory. Much of nucleic acid hybridization research is
proprietary, and a particular challenge is todevelop a meanswhereby information can beused for
the progress ofscience as a whole when generated by private ownership.
THEORETICAL BASIS OF NUCLEIC ACID HYBRIDIZATION
The chemical basis for nucleic acid hybridization assays rests in the reversible
helix-coil transition of the nucleic acid molecule. Nucleic acids will associate as
double-stranded molecules or disassociate into single-stranded polymers conditioned
on the physico-chemical parameters of temperature, base pair composition [1], ionic
strength of the milieu [2], and the concentration of denaturing agents [3]. The
conditions which permit us to manipulate the association and disassociation of the
nucleic acid polymer strands are being intensely investigated in order to develop
nucleic acid hybridization (NA hybridization) probes that can be applied to the
diagnosis ofhuman infectious diseases.
Much of the theoretical and applied research of NA hybridization technology
concerns factors affecting the stringency ofthe interaction ofthe nucleic acid strands.
Complementary single-stranded nucleic acid associates according to second-order
kinetics, the major rate-determining parameter being the number of complementary
sequences between the polymer strands [4]. The amount ofnon-homology that can be
tolerated while still achieving association between the two strands under particular
conditions is known as stringency. Stringency may be manipulated by varying the
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TABLE 1
Cloning Protocol
Step DNA Hybridization Monoclonal Ab
Selection oftemplate Restriction endonuclease and cap- Immunization ofanimal and cap-
ture of DNA fragments ture of,B-lymphocytes
Insertion oftemplate Ligation to a plasmid-insertion in Fusion with a thymidine kinase
recipient E. coli negative myeloma cell
Selection ofactive template Successful insertion shown by an- Successful fusion by growth in
tibiotic sensitivity HAT medium (thymidine ki-
nase activity restored)
Amplification oftemplate product Growth ofvector E. coli Growth offused ,B-lymphocyte/
myeloma cells
Selection ofclones with desired DNA hydridization Immunoassay
properties
temperature, the time, and the ionic strength of the milieu. High stringency implies a
great deal of specificity between nucleic acid hybrids with large numbers of base pair
matches; low stringency implies a relatively small number of base pair matches, yet
enough to yield a double-stranded moiety.
For the diagnosis of human microbial diseases, NA hybridization reactions occur-
ring at conditions requiring high stringency will detect closely related pathogens.
Conditions that utilize low stringency, even with the same NA hybridization probe, can
detect an entire genus or family ofmicroorganisms. For example, a nucleic acid probe
at high stringency conditions may detect only Herpes simplex virus type I, whereas at
low stringency the entire genus ofherpes virus may be detected [5].
Recombinant nucleic acid technology is being used in three major ways. First, one
can isolate specific DNA fragments from a complex mixture of DNA molecules and
amplify them in milligram quantities; the diagnosis of infectious diseases falls in this
category and will be considered in detail. Second, one can alter DNA molecules by
inserting or deleting restriction endonuclease recognition sites; in effect, one can create
new genes. Third, one can synthesize large amounts ofpeptides or proteins in bacteria
or eukaryotic cells.
PROCEDURE FOR MAKING NA HYBRIDIZATION PROBES
There are four essential steps in producing an NA hybridization probe [6]. A
specific nucleic acid fragment from the microbial pathogen must first be isolated; this
fragment must be specific to the organism under study. Second, the fragment has to be
inserted into a vector, or vehicle; this vector must be one that can accept foreign DNA
and replicate in a living cell; semi-synthetic plasmids have been developed for this
purpose. Third, the vector must be introduced into a host organism with the host not
only accepting the vector but replicating it when the host itselfreplicates. Fourth, one
must screen large numbers of cells to capture the desired recombinant clone. Table 1
presents the essentials steps in the cloning protocols of both NA hybridization and
monoclonal antibody technologies.
A finding that allowed the development of NA hybridization probes was the
discovery of restriction endonucleases. Restriction endonucleases are enzymes that
specifically cut nucleic acid sequences within the polymer molecule. Type I restriction
endonucleases are complex proteins of two to eight subunits that require ATP,
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TABLE 2
Commonly Employed Restriction Endonucleases in the Diagnosis of Infectious Diseases
Enzyme Name Species Sequence Attacked
EcoRl Escherichia coli (with plasmid RI) 5'-G-A-A-T-T-C-3'
Bam HI Bacillus amyloliquefaciens 5'-G-G-A-T-C-C-3'
Hind III Hemophilus influenzae 5'-A-A-G-C-T-T-3'
Hpal Hemophilusparainfluenzae 5'-G-T-T-A-A-C-3'
Hae III Hemophilus aegypticus 5'-G-G-C-C-3'
Hinc Haemophilus influenzaeR., 5'-G-T-Py-Pu-A-C-3'
Hinf I Haemophilus influenzae Rf 5'-G-A-N-T-C-3'
Alu I Arthrobacter luteus 5'-A-G-C-T-3'
N-adenosyl-L-methionene, and magnesium. These enzymes hydrolyze randomly.
Type II restriction endonucleases are simple proteins that require only magnesium for
function. These cut double-stranded nucleic acid polymers at defined points. Type II
restriction endonucleases are the kind utilized in nucleic acid hybridization research
[5].
Restriction endonucleases are produced by microorganisms to eliminate foreign
DNA from themselves. The host protects itself from its own restriction endonuclease
by methylating the base pair target sequence [7]. There are now several hundred
restriction endonucleases available from commercial sources. Examples of the com-
monly employed restriction endonucleases used for the diagnosis ofinfectious diseases
and the specific sequences they attack are presented in Table 2. Knowing the
specificities ofthe enzymes, one may choose restriction endonucleases to yield nucleic
acid fragments of known size distributions from the microbial pathogen. Practically,
one grows the microbial pathogen in large numbers, removes its nucleic acid by a
combination ofphysical (sonication) and chemical (detergents and alkali) means, and
cuts the nucleic acid into small pieces with specific restriction endonucleases. The
small pieces are separated from each other by electrophoresis on gel and column
chromatography. The investigator chooses those pieces based on size distribution or
other particular parameters for insertion into a cloning vector [5,8].
Bacterial DNA can be utilized directly in a nucleic acid hybridization probe assay.
From viruses and eukaryotic pathogens, however, one must make complementary
DNA (cDNA). RNA is generally cloned indirectly. RNA can be converted into DNA
utilizing a reverse transcriptase enzyme from retroviruses. Utilizing the RNA as a
template, single-stranded cDNA is produced. The RNA can be eliminated from
cDNA in the mixture utilizing RNAse. A complementary second strand ofDNA may
be made to the cDNA, using DNA polymerase. This second strand of DNA is a DNA
copy ofthe original RNA polymer. The double-stranded cDNA can then be utilized to
produce NA hybridization probes. Table 3 presents the essential steps in the synthesis
ofcomplementary DNA [5].
The field is at present in a state offlux concerning which type of nucleic acid to use
as a probe target and which to use as the probe. Most work has been done with DNA
hybridization, but a growing body ofevidence indicates that for clinically useful tests
RNA may be preferable. DNA has the major limitation in that a particular specific
sequence may be present only once in a given cell. Ribosomal RNA or mRNA may
have a sequence repeated many times in the cell. Theoretically, therefore, the
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TABLE 3
Synthesis of Complementary DNA
Step Process Mechanism
Cell lysate Detergent/pH Disruption
Total cellular RNA RNA selection Precipitation
Total mRNA Bind 3' polyadenylate tail Poly dT binding
cDNA cDNA-mRNA complex Reverse transcriptase
Single-stranded cDNA RNA destruction Selective digestion ofRNA
Double-stranded cDNA Reverse transcription Enzyme linking
sensitivity of an RNA method should be greater than a DNA hybridization method
[8].
Recently Brenner reported the ability to specifically detect Legionella, utilizing
ribosomal RNA probes [Brenner DJ: Abstracts of the Annual Meeting of the
American Society for Microbiology, 1985]. He found that probes to the ribosomal
RNA of Legionella were not only specific but, because of the physical properties of
ribosomal RNA, the hybridization procedure could take place within one hour. He
utilized a commercially produced probe (Gen-probe, Irvine, CA).
Also in a state of flux is the means of selection of the fragments. Two possibilities
have been investigated: cloning ofall fragments from a pathogen ("shotgun cloning")
and pre-selection. Shotgun cloning methods were first used and are still the most
common. Many fragments ofsimilarsize distribution from the microbial pathogen are
inserted into vectors. Each vector is cloned and amplified, and each clone must be
tested for specific utility. Current research is directed at largely eliminating this
tedious task by pre-selecting specific fragments from the restriction endonuclease
digest before they are inserted into the cloning vectors. Most intensely being studied
are affinity chromatography methods to pre-select desired fragment(s). The desired
fragment(s) stick to thecolumn while unwanted fragments pass through it. The proper
fragment(s) are eluted from the column to be inserted into the vector.
The cloning vector is either a plasmid, bacteriophage, or a genetically engineered
plasmid known as a cosmid. The nucleic acid must be inserted into a vector with both
the vector and the nucleic acid retaining function. The vectors are extra-chromosomal
and can betransferred toa hostorganism. Each timethehostorganismreplicates once,
thevector replicates at leastonce. Table4 presents thecommoncloningvectors utilized
for the construction ofNA hybridization probes for thediagnosis ofinfectious diseases
[5,8].
The nucleic acid fragment is inserted into the vector, utilizing specific restriction
endonucleases. The vector contains single recognition sites for one or more restriction
endonucleases. The common vectors have been genetically engineered and have been
completely sequenced. Each vector has a particular selection marker so that there is a
signal to detect if the insertion has been successful. A vector with both plasmid and
microbial DNA is known as a chimera. For example, the vector plasmid pBR322
contains genes that confer resistance to the antibiotics ampicillin and tetracycline. If
one chooses a restriction endonuclease that cuts the plasmid in the tetracycline
resistance gene toinsert thenucleicacid fromthemicrobe here, tetracycline resistance
is lost. Accordingly, once this plasmid is transferred to a host bacterium, successful
insertions will beobserved by resistance only toampicillin. Unsuccessful insertions will
be resistant to both ampicillin and tetracycline.
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TABLE 4
Commonly Utilized Cloning Vectors
Vector Name Selection Marker Source Use
pBR322 Ampicillin tetracycline Laboratory construct of Expression in E. coli, used for
resistance three naturally found constructing new cloning
plasmids vectors; e.g., pSP64 and
pUC
pSP64 Ampicillin resistance Laboratory construct For producing RNA hybridi-
zation probes in vitro
Ml3 series Beta-galactosidase Natural DNA sequencing and DNA
hybridization probes
pUC series Ampicillin resistance and Laboratory construct DNA sequencing and expres-
beta-galactosidase sion in E. coli
Practically, one selects a restriction endonuclease to cut the particular vector in a
specific spot. The nucleic acid is inserted into this sequence and the vector reassociated
with a DNA ligase. The vector is then inserted into a receptive host.
The host ordinarily utilized to make NA hybridization probes for the diagnosis of
infectious diseases is Escherichia coli, the most commonly utilized being E. coli K12.
This Escherichia coli is sensitive to all commonly utilized antibiotics, accepts the
vector efficiently, and replicates the vector at least once every time it multiplies. In the
cloning protocol, the susceptible E. colihasavailable to it twovectors: a chimera with a
successful insertion and a reannealed vector that did not accept a nucleic acid piece.
The vectors are mixed in liquid growth medium with the host E. coli, with three
possible outcomes: an E coliwith no vector, an E. coliwith a reannealed vector, and an
E. coli with a chimeric vector. The mixture is spread over the surface of an agar
medium to select only the E. coli with chimera. Colonies oftransformed bacteria, each
E. coli in the colony containing at least one copy ofthe chimeric plasmid, are grown in
large numbers. The cells are harvested and the copies ofthe original microbial nucleic
acid released, utilizing specific restriction endonucleases [5,8].
The cloned microbial DNA must be labeled to be utilized as a nucleic acid
hybridization probe. Traditionally, labeling has occurred by a nick translation process
[9,10]. Single-stranded nicks are introduced into double-stranded DNA, utilizing
DNAase I. These nicks are subsequently repaired, utilizing a DNA polymerase I in the
presence of32P-labeled deoxyribonucleotide triphosphates. Activity levels of 108 counts
per minute per microgram of DNA can be obtained. Single-stranded DNA probes
capable of detecting 0.1 picogram of target DNA result. The minimum sensitivity of
an individual nucleic acid hybridization probe will depend on the size of the genomic
target and the percentage ofhomology between the probe and the target.
Research is being conducted to eliminate radiolabeling by replacing 32p with a
non-radioactive signal. The first non-radioactive signal to achieve widespread use was
the synthesis of biotin-labeled analogues of deoxyuridine triphosphate and uridine
triphosphate. Biotin was covalently linked to the C5 position of the pyrimidine ring
through an allylamine linker arm [11]. It was found that the attachment of biotin to
the nucleic acid did not affect the association properties. Linker arms of various
lengths wereemployed toattach biotin tonucleicacid, the most usefulbeing a length of
approximately 11 units (see Fig. 1). Table 5 demonstrates the differences between
radiometric and non-radiometric, biotin-labeled probes [12].
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FIG. 1. Attachment of biotin to
nucleic acid, utilizing linker arms of
various lengths.
Nucleic acid hybridization probes labeled with biotin can be detected by either
immunochemical or enzymatic methods. The strong avidity of biotin for avidin has
been most successfully exploited. This protein has an avidity of Kd = I0-5, with four
binding sites for biotin [13]. One or more ofthe avidin binding sites can be labeled with
an enzyme such as horseradish peroxidase [14] or alkaline phosphatase [12]. If the
biotin-labeled NA hybridization probe attaches to microbial nucleic acid, biotin will be
available for reaction with avidin. If one adds avidin to which an enzyme has been
attached, and subsequently a colorimetric substrate for the enzyme, the interaction of
the probe with microbial nucleic acid can be directly visualized. The sensitivity of
biotin-labeled NA hybridization probes has recently been increased significantly,
utilizing polymerized alkaline phosphatase attached to avidin [15].
Another strategy to detect the interaction of the NA hybridization probe with
microbial nucleic acid polymer is the utilization ofantibody specific to the nucleic acid
complex. Although patients with systemic lupus erythematosus have anti-nuclear
antibodies, the direct antibody detection of nucleic acid complexes has not proven
efficacious. Recently a technique has been developed to label nucleic acid with a
hapten [16]. Antibody to the hapten is used to detect the hybridization. Tchen et al.
[17] found that guanine residues in nucleic acids could be labeled with N-acetoxy-
N-2-acetylaminofluorene (AAF) and its 7-iodo (AAIF) derivatives (see Fig. 2). These
TABLE 5
Labeling the Nucleic Acid Probe
Step Radiometric Non-Radioactive (Biotin)
Choice ofsignal 32p Biotin:Avidin:Enzyme
Insertion ofsignal Nick translation Covalent enzymatic linking ofbiotin to
pyrimidine ring
Reading ofsignal Direct Indirect
Developer None Avidin to which an enzyme is attached
Measurement Radioactive counts Detection ofenzyme activity by addi-
(generally film tion ofsubstrate
exposure)
Stability 32P half-life 14.3 days - 200C for two years
Precautions Radioactivity None
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I FIG. 2. The haptens M-acetoxy-N-
R1 2-acetylaminofluorene (AAF) and its
R, = 1 '-ribosyl or 1 '-deoxyribosyl; R2 = H (AAF) or I (AAIF) 7-iodo derivatives (from [17]).
AAF or AAIF derivatives could be directly detected in an immunochemical
sandwich-type assay. If the hapten-labeled probe attached to microbial nucleic acid,
the hapten was exposed. Antibody labeled with a signal, such as an enzyme, fluorescent
dye, and so on, bound to the hapten and yielded a positive test (see Fig. 3).
Recently, a procedure to produce large quantities of RNA hybridization probes,
which are ten times more sensitive than DNA hybridization probes, was published
[18,19,20]. The method utilized the RNA vector SP6. Chemically, DNA/RNA
hybrids are more temperature-stable than DNA/DNA hybrids. Accordingly, RNA
hybridization probes can be utilized under higher stringency conditions than those
which permit DNA polymers from associating. Working under these different
physico-chemical conditions permits the detection ofsmaller numbers ofpathogens.
Other strategies to label nucleic acid have been explored but as yet have not proven
clinically efficacious. Signal molecules have been introduced into nucleicacid, utilizing
nucleotide analogues that function as substrates for nucleic acid polymerases [11,12].
Also, glycosylated T4 bacteriophage DNA, whose carbohydrate-modified nucleotides
can act as natural signals, have been synthesized [21].
The future research and development of NA hybridization probe analysis of
microbial pathogens will beconcentrated in exploiting colorimetric methods. Color has
obvious advantages over radioactivity, not the least being it can be packaged for
markets ranging from large laboratories to private, over-the-counter tests. Colorimet-
ric methods are approaching the sensitivity of radiometric procedures [22]. The time
required for color development has been significantly shortened in the last years, from
24 or more hours to same-day readability. By polymerizing the alkaline phosphatase
attached to avidin, color could be measured within two hours [15,23].
DNA AAF probe
or or first
RNA AAIF antibody
+ + target + k
second stain
antibody
FIG. 3. Procedure for the preparation and detection ofimmunonucleic probes (from [17]).
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After the nucleic acid has been captured from the microbial pathogen, inserted into
a vector, amplified in E. coli, and labeled, the last step in thediagnosis ofan infectious
disease using an NA probe is the assay itself. Current assays utilize solid support
hybridization methods. By analogy to immunological techniques, these will be referred
to as heterogeneous methodologies because several washing steps are required to
remove bound from unbound reactants. Homogeneous techniques, in which the
reaction occurs in a liquid mediumwithout therequirementtoseparatethe bound from
the unbound, have not as yet been developed for NA hybridization.
There are four basic assaytechniques in use. The mostextensively studied is thedot,
or dot-blot, hybridization technique. This method employs a nitrocellulose filter paper
support. A sample from the patient containing the infectious microbe is disrupted to
release its nucleic acid. The nucleic acid is bound in a spot on nitrocellulose by a
combination ofphysical (heating) and chemical (salts, detergents) means. The labeled
NA hybridization probe is added to the spot under particular stringency conditions. If
there is complementary nucleic acid from the patient's sample, the labeled nucleic
hybridization probe will be bound; if there is no complementary nucleic acid on the
spot, the hybridization probe will not be bound and can be easily washed away. A
substrate to the label on the NA hybridization probe is added and the reaction
measured. If the label is 32P, the measurement involves the overnight development of
photographic film. If the label is an enzyme, the measurement may be either by
densitometry or by direct visualization [12].
Varying the arm length of the biotin-labeled target, the concentration and types of
signals, and the utilization of polymerized alkaline phosphatase, dot hybridization
procedures can detect as little as 1-2 picograms of target sequence (refer to Table 6)
[15,22,23]. The clinical utility of dot hybridization analysis has been demonstrated
with hepatitis B virus [24,25], cytomegalovirus [26], adenovirus [27], and herpes virus
[28]. Other viruses and microbial pathogens are currently under clinical investigation
[8]. Of particular interest is the ability to elucidate viruses that cannot be cultured
directly from clinical samples.
The clinical utiliy ofdot hybridization has significantly progressed, especially in the
ability to manipulate nucleic acids and eliminate contaminating proteins and other
inhibiting substances from specimens. Traditionally, NaCl was utilized as part of the
stringency conditions to fix DNA to nitrocellulose. It was found that RNA which
lacked poly(A) did not bind to nitrocellulose. Subsequently it was discovered that
changing the salt from NaCl to Nal allowed mRNA to fix specifically to nitrocellulose
[29,30]. Not only did mRNA bind, but DNA and many proteins did not stick to
nitrocellulose. The NAI seemed to promot mRNA nitrocellulose interaction, solubilize
the pathogenic cell, and did not promote the interaction of DNA with nitrocellulose.
Adding or subtracting detergents such as brij-35 and DOC allowed one to affix
selectively either DNA or mRNA to nitrocellulose [29,30].
Sandwich hybridization techniques are currently under development and have been
utilized to detect virus from clinical specimens (Fig. 3). This methodology involves the
production oftwo non-complementary nucleic acid sequence reagents. These reagents
are produced fromadjacent sites on the microbial pathogen's genome. The first nucleic
acid sequence is immobilized on to the solid nitrocellulose support and serves as a
target sequence to interact with nucleic acid from the microbial pathogen. The second
sequence is labeled and serves as the nucleic acid detector probe. Like dot hybridiza-
tion, nucleic acid is first extracted from the clinical sample. The extracted nucleic acid
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TABLE 6
Relative Sensitivity of Biotin-Specific Reagents in Detecting Biotin-Labeled Polynucleotides
Bound to Nitrocellulose Filters
Bio-DNA Detection Limits
Target Detector Reagents Substrates (pg Target Sequence)
1. Bio-4 Anti-biotin IgG + FITC-20 Ab 2,000-4,000
2. Bio-1 1 Anti-biotin IgG + FITC-20 Ab 500-1,000
3. Bio-4 Anti-biotin IgG + HRP-20 Ab DAB/EAC 500-1,000
4. Bio-1 1 Anti-biotin IgG + HRP-20 Ab DAB/EAC 150-200
5. Bio-4 ABC (avidin DH-Bio HRP) DAB/EAC None detected
6. Bio-11 ABC DAB/EAC 75-150
7. Bio-16 ABC DAB/EAC 75-150
8. Bio-16 Anti-biotin IgG + Bio-20 Ab + ABC DAB/EAC >100-200
9. Bio-16 ABC + Bio-DNA + ABC DAB/EAC -100-200
10. Bio-16 ABAP (Avidin-Bio Alk. Phos.) NBT + BCIP 20-30
11. Bio-16 poly ABAP (avidin-poly Bio Alk. Phos.) NBT + BCIP 1-2
Abbreviations: Bio-4-dUTP, Bio- 1-dUTP, and Bio-16-dUTP-analogues ofTTP thatcontain a biotin
molecule linked to the C-5 position ofthe pyrimidine ring through linker arms that are4, 11, and 16 atoms
long, respectively. Bio-4-DNA, Bio- 1-DNA, and Bio-16-DNA-DNA probes prepared with Bio-4-,
Bio-11-, or Bio-16-dUTP analogues, respectively. NBT-nitro blue tetrazolium. BCIP-5-
bromo-4-chloro-3-indolyl phosphate. DAB-3.3'-diamino-benzidine. EAC-ethyl amifiocarba-
zole. ABAP-complexes of avidin and biotinylated alkaline phosphatase polymers. NaCl/
Cit-standard saline citrate (0.15 M CaCl/0.015 M sodium citrate, pH 7.0). From [11]
is mixed with the probe nucleic acid and hybridized against the target sequence, which
has been bound to nitrocellulose paper. Particular stringency conditions are obeyed. If
the microbial pathogen nucleic acid is complementary to both the probe reagent
nucleic acid and the filter-bound nucleic acid, a sandwich will be formed and the
complex detected by the addition of a developer to the probe label [31]. Utilizing this
technique, as little as 8 x 10-18 mols (approximately 5 x 106 molecules) ofDNA from
adenovirus can be detected [32]. This level of detection is comparable to radioimmu-
noassay, and the time of detection, approximately 20 hours, is significantly less than
the days required for viral culture.
In 1975 Southern described a method for analyzing specific DNA fragments from a
complex mixture. This method has become standard to establish the specificity of
nucleic acid sequences. After restriction endonuclease digestion, the mixture is
separated by agarose gel electrophoresis. The DNA fragments are transferred by
either blotting or electroelution to nitrocellulose paper. Nucleic acid hybridization
probes are added to the nitrocellulose paper to establish identity. The major limitation
ofthe Southern technique for clinical use is that it requires large amountsofDNA and
restriction endonucleases and is quite time-consuming. A modification ofthe Southern
technique to analyze RNA, commonly known as the "Northern" technique, has
become standard to establish thespecificity ofRNA [12]. The Northern technique has
not yet been utilized in the clinical setting.
The last major heterogeneous technique utilized to detect infectious agents by NA
hybridization is insitu hybridization. Here, human tissue is treated with a combination
of dilute detergents, mild acid, and proteases on a nitrocellulose support. This
treatment fixes the cells in their natural configuration while allowing the introduction
of a labeled NA hybridization probe. Analogous to the fluorescent antibody detection
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FIG. 4. Examples ofthe detection of herpes simplex virus types I and II from patient's specimens utilizing
a32P-labeled nucleic acid probe (from [35]).
of microbial pathogens within tissue, in situ hybridization allows the direct visualiza-
tion of nucleic acid sequences as they occur in vivo. This method has proven
particularly useful in detecting viruses from tissue specimens. Brigati et al. [22] were
able to detect parvovirus, polyomavirus, herpes simplex virus, adenovirus, and retrovi-
rus genetic material from infected cell cultures. They further demonstrated the
presence of herpes virus and adenovirus DNA in paraffin-embedded autopsy tissue;
they utilized a biotin-labeled DNA probe. Myerson et al. could detect cytomegalovirus
in open lung biopsies within 24 hours. They constructed their probe from seven
different cytomegaloviruses to ensure that no member of this genus would be missed
[33,34].
In situ hybridization will most likely find its greatest applicability in the research
environment. It is too labor-intensive and yields too little quantitative information for
clinical utility.
CLINICAL UTILITY OF NUCLEIC ACID HYBRIDIZATION PROBES
From the first description oftypeII restriction endonucleases in 1975 until the early
1980s, the clinical utility of NA hybridization probes was in the developmental stages.
Within the last three years, methods have been developed to translate the basic
research to tests which can be utilized in the clinical laboratory. The technology is
rapidly developing with any given procedure and limits of detection likely to become
rapidly historical.
In 1982 Chou and Merrigan reported the detection and quantitation ofcytomegalo-
virus from human urine specimens, utilizing DNA hybridization with32p [26]. They
were able to detect as few as1IO viruses per milliliter of urine. Ward and his associates
were able to detect herpes simplex virus directly from clinical lesions, utilizing a
dot-blot hybridization technique [22]. Torres et al. [66] have detected105 Haemophi-
lus influenzae from cerebrospinal fluids, utilizing 32P-labeled DNA hybridization
probes. Redfield et al. [35] quantitated herpes virus from human lesions. Autoradio-
graphs ofthe hybridization of32P-labeled nucleic acid hybridization probes ofa typical
assay are presented in Fig. 4. DNA was extracted by centrifugation at 10,000 g
followed by the addition of0.3 M sodium hydroxide, heating for one hour at 600C, and
the addition of2 M ammonium acetate. The specimens were dotted on to nitrocellulose
paper. The nitrocellulose blots were air-dried and baked for two hours at 800C before
hybridization. The probe was a DNA BAMH1 restriction endonuclease fragment with
a molecular weight ofapproximately 7 x 106. It was cloned in plasmid pRBl 31. Their
technique had a sensitivity of 78 percent and a specificity of 100 percent compared to
standard viral culture. No hybridization was observed with related viruses.
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TABLE 7
DNA Hybridization Assays with Potential for Diagnostic Application
Pathogen Probe Specimen Examined Reference
Enterotoxin-producing E. coli Heat-labile and heat-stable Stool isolates [57, 58]
toxin genes Stool specimens [58]
Contaminated food isolates [59]
Gonococcus Gonococcus cryptic plasmids Swabs ofmale urethra [28]
Cytomegalovirus Selected viral fragments Urine [26, 60]
Buffy-Coat Cells [60, 61]
Lung Tissue [60]
Epstein-Barr virus Viral DNA Various infected lymphoid [62]
cell lines
Herpes simplex virus Thymidine kinase gene and Viral isolates [27]
viral DNA fragments
Adenovirus Two probes used in a double- Swabs ofnasopharynx [32]
sandwich assay
Viral DNA Stool specimens [63]
Hepatitis B virus Viral DNA Liver [64]
Serum [64, 65]
There are no currently available commercial kits to diagnose infectious diseases by
NA hybridization, although intense effort is under way to produce them. Table 7
presents hybridization assays that have been utilized to diagnose infectious diseases
from clinical specimens under field conditions [8,26,28,57,58,59,60,61,62,63,64,65].
The major hurdle to overcome before NA hybridization is available to the clinical
laboratory is the translation of the basic, one-test-at-a-time research into procedures
capable of being performed in large numbers with minimal human interpretation. In
order for the nucleic acid hybridization techniques to be clinically useful, several
modifications from published procedures must occur. First, 32p must be replaced with a
colorimetric system; the colorimetric developer must be rapid enough to ascertain
positivity within two to four hours. Second, the nucleic acid hybridization probe must
have a sensitivity of IO0 organisms/ml; currently, the limit of detection is approxi-
mately 105/ml. Third, the hybridization probe, whether DNA or RNA, must be broad
enough to detect all members of a given species; for example, the hybridization probe
mixture used by Chou and Merrigan [26] to detect cytomegalovirus contained probes
against seven different strains ofthis virus. Fourth, probes must be developed to detect
resistance to antibiotics; one must learn both the name of the pathogen and which
drugs are active against it. Fifth, homogeneous assays must be developed to replace
currently employed heterogeneous technologies; homogeneous assays are much less
costly and labor-intensive. Sixth, because a single probe can detect only one parameter,
instruments must be developed to automate the very large number ofprocedures that
must be performed on each clinical specimen. If, for example, one wishes to examine
cerebrospinal fluid, one would have to test probes for a large number of bacteria,
viruses, and yeasts plus many antibiotic resistance factors; this large battery of tests
virtually precludes manual performance.
MONOCLONAL ANTIBODIES
It is beyond the scope of this paper to present in detail the manner by which
monoclonal antibodies are produced [41]. Table 1 presents the essential steps in
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monoclonal antibody production and compares them with the parallel steps used to
produce NA hybridization probes. The reader is referred to the review by Engleberg
and Eisenstein [8] for further details.
Although the technology to produce in large amounts monoclonal antibodies against
selected antigens dates from the mid-1970s, immunochemistry as a sciencedates to the
1930s. By the time means to make monoclonal antibody wasdiscovered, the knowledge
to purify and produce antibody-based laboratory kits was well established. According-
ly, while there is still much to be learned about the translation of research data to
clinical applicability, monoclonal antibody technology is in a significantly more
advanced state than NA hybridization. Commercial kits utilizing monoclonal antibod-
ies for the diagnosis ofinfectious diseases became available in 1983 [42].
Analogous to NA hybridization, both the strength and the weakness of monoclonal
antibody technology lie in its extreme specificity. A monoclonal antibody against an
epitope in a highly variable portion of a pathogen's surface, like hybridization done
under extreme stringency conditions, will not likely recognize related members of the
same species. Therefore, both technologies can require multiple monoclonal clones to
detect a particular species ofpathogen [43].
A second limitation of monoclonal antibody technology lies in the reactivity of the
antibody itself. The combination ofantigen with antibody is a primary reaction, which
we do not directly measure. We assay a secondary product ofthis interaction such as
precipitation, agglutination, and the like. It has been found that the avidity constants
of monoclonal antibodies to epitopes are of a relatively low order of magnitude, thus
limiting the types ofdetection systems one may employ. In the same vein, a particular
monoclonal antibody may react well in one secondary system, such as a radioimmu-
noassay, but not at all in another system, such as complement fixation. This limitation
is particularly important for the clinical laboratory because one ideally would want to
develop a central technology, such as enzyme-linked immunosorbent assay (ELISA),
to process the large number of tests required with monoclonal screenings.
Third, unlike NA hybridization, where one can select a particular base pair
sequence specific for an organism, microbes may have large numbers of different
antigens capable of eliciting monoclonal antibody responses. While these large
numbers ofepitopes enhance the likelihood that one could be found specific for a given
species, it also increases the likelihood that two or more species may share a particular
antigenic determinant. Fourth, because these antigenic sites are so small, the theoreti-
cal possibility exists that they may be more prone to phenotypic variation. This
variation could occur notonly by mutation but also becauseofthegrowth environment,
nutrient mix, atmospheric conditions, and the loss or acquisition of plasmids. Fifth,
antigens useful for in vitro testing may not be expressed or may be hidden in vivo
[43].
A wide variety ofheterogeneous and homogeneous immunological assay procedures
have been developed in the last ten years for both polyclonal and monoclonal antibody
technology. For the diagnosis of infectious diseases, the first widely utilized technique
for the detection of pathogens in body fluids was counterimmunoelectrophoresis,
developed in the early 1970s. This procedure was replaced by latex particle agglutina-
tion and co-agglutination tests in the early 1980s. Latex agglutination utilizes
polystyrene beads to which a monoclonal antibody is adsorbed in the Fc region.
Co-agglutination utilizes Staphylococcus aureus that has protein A on its surface.
Protein A binds the Fc portion of IgG. With both latex and co-agglutination
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TABLE 8
Lower Limits of Antigen Detection by Counterimmunoelectrophoresis
mcg/ml Approximate Number
Species Antibody Source Ag ofBacteria/ml
Hemophilus influenzae b Commercial 0.01 104
Streptococcus pneumoniae Statens Serum Institute 0.05 105
Neisseria meningitidis A Commercial 0.05 l05
Neisseria meningitidis C Commercial 0.10 5 x 105
Streptococcus agalactae BIII Commercial 14.0
Streptococcus agalactae Bll Burro 0.7 5 x 105
techniques, the body fluid is mixed with a suspension of the antibody-coated particles
and, if antigen is present, agglutination occurs in minutes. The reactions are read
manually. Clinical studies utilizing particle agglutination technology have recently
been published and appear to be between five and ten times more sensitive than
counterimmunoelectrophoresis methods. Counterimmunoelectrophoresis, which has
been well studied with many bacterial pathogens for a decade, can detect between 104
and 1O' bacteria/ml (refer to Table 8) [42].
Particle agglutination technology is not amenable to automation and is labor-
intensive. Furthermore, the large battery of individual procedures required by mono-
clonal antibody technology limit its usefulness in the routine clinical laboratory.
Accordingly, the research thrust has been to develop instrumented homogeneous
enzyme immunoassay tests. Enzyme immunoassays for Haemophilus influenzae type
b have been developed and can detect 1 ng/ml of the polyribophosphate antigen
[44,45,46,47]. ELISA procedures have also been described for other agents of
meningitis, including Streptococcuspneumoniae, Neisseria meningitidis, and group B
Streptococcus [48,49,50,51]. These assays are in development. Like NA hybridiza-
tion, workers are experimenting to automate the large numberofindividual procedures
that must be performed on a clinical specimen by monoclonal antibody technology.
Enzyme labels useful for monoclonal antibodies are also useful in the secondary
detection systems and automated instruments for NA hybridization. Because the time
and intensity of color development is currently the rate-limiting step for both
technologies, a large number of enzymes and physico-chemical conditions have been
studied. Table 9 presents those enzymes showing the most promise with the conditions
under which they are optimally active and the means by which they are detected
[52].
The clinical utility of monoclonal antibodies in infectious diseases has centered in
five major areas. First, and of most immediate clinical utility, is the identification of
specific antigens for diagnostic purposes. A major limitation of monoclonal antibody
technology is its inability to recognize antibiotic resistance. Second has been the
elucidation ofspecific antigens to establish if two organisms are the same or different.
This application for grouping has been most actively pursued in thefield ofepidemiolo-
gy. Third, considerable work has been done on the mechanisms whereby microbial
surface structures play roles in virulence. Monoclonal antibodies may be useful in
treating a variety of infections and microbial toxicoses [53]. Fourth, monoclonal
antibodies have proven useful in studying the transport of materials into and out of
cells.
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The clinical utility of monoclonal antibodies in diagnosis has thus far not signifi-
cantly displaced polyclonal tests. Monoclonal antibody tests are commercially avail-
able for the direct detection of group A Streptococcus from throat cultures and
chlamydia from urethritis. Monoclonals have also been utilized to aid in the identifica-
tion of microorganisms after they have been grown in vitro. Monoclonals have proven
more useful than polyclonals for this purpose, particularly for Neisseria gonorrhoeae,
Legionella, chlamydia [8], and herpes [54].
COMPARISON OF NUCLEIC ACID HYBRIDIZATION AND
MONOCLONAL ANTIBODY TECHNOLOGIES FOR THE
DIAGNOSIS OF INFECTIOUS DISEASES
There are no published studies directly comparing a monoclonal antibody and an
NA hybridization technique for the diagnosis of the same pathogen in a clinical
setting. As mentioned above, polyclonal antibody systems have been utilized to detect
pathogens directly from body fluids since the early 1970s. These characteristics are
well established [42,55,56]. Monoclonal tests will certainly be at least as sensitive as
polyclonal systems. It is too early to predict the sensitivities and specificities of NA
hybridization tests when they reach the clinical laboratory. Therefore, monoclonal
antibody and nucleic acid hybridization technologies are in unequal states ofdevelop-
ment. One should expect much greaterchange in nucleicacid hybridization technology
compared with monoclonal antibody techniques. The primary research and develop-
ment ofdetection systems for monoclonals lie in the production ofsimple instruments
with appropriate enzyme labels for measuring reactivity. NA hybridization has much
further to go. For example, it has not yet been decided which nucleic acid to choose to
analyze. Furthermore, the system for releasing nucleic acid from the infecting microbe
is not yet satisfactory. Before instrumentation can be developed, these major obstacles
must be overcome.
A barrier impeding the rapid development ofNA hybridization procedures that did
not exist in the early 1970s for the development of immunochemical methodologies is
the paucity of published information. The majority of work in the NA hybridization
field is proprietary and is not being published. It may be that many of the
above-mentioned problems have been solved, perhaps solved several times in different
places, but are not available to the independent scientist. Progress will be hindered by
this lack ofpublic information. The intermediate steps necessary before a final product
is generated will have to be discovered, analyzed, and overcome in multiple individual
settings. This massive redundancy ofscientific investigation is unprecedented.
The technology presented to the clinical laboratory for NA hybridization diagnosis
will probably use a combination of nucleic acid probes and monoclonal antibodies.
DNA can be labeled with a hapten, following the work ofWard et al. and Tchen et al.,
to produce the hybridization probe. The probe itself, after reacting with the pathogen's
nucleic acid, can be detected by monoclonal antibody directed to the hapten. Attached
to the monoclonal antibody would be an enzyme label, which could be detected in a
homogeneous system with inexpensive instrumentation. The procedure, analogous to
the standard microtiter tray antibody assays, would be performed in small wells,
reducing the cost and quantities of reagents. Each well would detect one genetic
element. For each specimen the wells could be inoculated, incubated, and read by the
instrument.
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The clinical laboratory's choice to use either NA hybridization or monoclonal
antibody will not be an either/or one. Some microbial pathogens will probably be more
amenable to diagnosis by one technology than the other. The technology that can
provide the greatest amount ofclinically useful information with the fewest procedures
or individual analyses required should achieve primacy.
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